Neuphoria plunges after trial failure forces halt to anxiety drug program

Neuphoria Therapeutics

20/10/2025 22:11

** Shares of drug developer Neuphoria Therapeutics NEUP.O fall 72% to $4.30 in extended trading

**  Co says its experimental drug for social anxiety disorder failed to show benefit in a late-stage trial, prompting NEUP to halt development of the program

** Co was testing the drug, BNC210, in people with social anxiety disorder, but the drug did not meet its main goal of reducing distress during a public speaking challenge

** Co had $14.2 million in cash as of June 30 and expects that to last until the second quarter of 2027

** Co plans to consider developing BNC210 for post-traumatic stress disorder

** Stock up 349% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))